{ "docId": "019dd923-622b-71dc-a6da-7792191b0575", "docSlug": "ca94acfa263b", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 50, "pageCount": 74, "prevPage": 49, "nextPage": 51, "slideType": "testimonial", "function": "expose_contradiction", "density": "overcrowded", "nDataPoints": 1, "notes": "The slide uses external authority to validate a critique of management's capital allocation strategy.", "elementsJson": [ "headline_text", "callout_box", "quote_block" ], "metadataConfidence": 1, "imagePath": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-7792191b0575/50", "deckHref": "/decks/019dd923-622b-71dc-a6da-7792191b0575", "deckJsonHref": "/decks/019dd923-622b-71dc-a6da-7792191b0575.json", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-7792191b0575#slide-50", "components": [ { "bbox": { "h": 0.04, "w": 0.92, "x": 0.04, "y": 0.18 }, "kind": "callout", "text": "Select Quotes from Wall Street Research Analysts", "attrs": null, "subkind": "primary", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "740122f7-6ace-42ff-a494-4c077f879237", "frameworkName": null, "frameworkSlug": null }, { "bbox": null, "kind": "callout", "text": "Wall Street analysts were shocked by Pfizer's recall of OXBRYTA.", "attrs": null, "subkind": null, "toolName": "Visual emphasis", "toolSlug": "visual-emphasis", "confidence": null, "componentId": "019dd953-2b66-7100-896a-a2513372a286", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.25, "w": 0.92, "x": 0.04, "y": 0.25 }, "kind": "quote", "text": "Oxbryta pulled from market; $5.4bn GBT deal latest example of challenged BD track record... this will again raise questions on Pfizer's BD effort - feeding into old criticism around Pfizer's ability to pick winners through BD.", "attrs": null, "subkind": "testimonial", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "a358ad92-bceb-4f74-9ea3-9df78f5890d2", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.22, "w": 0.92, "x": 0.04, "y": 0.61 }, "kind": "quote", "text": "When you cover biotech and pharma - it's hard to find a headline that's truly jarring, but news that PFE is recalling Oxbryta/discontinuing all active trials after seeing a death/ VOC imbalance in clinical trials & lack of overall risk-benefit fits the bill.", "attrs": null, "subkind": "testimonial", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "f7c59615-d7ff-4a58-b711-2f2ce3017bf4", "frameworkName": null, "frameworkSlug": null }, { "bbox": null, "kind": "quote", "text": "\"Oxbryta pulled from market; $5.4bn GBT deal latest example of challenged BD track record... this will again raise questions on Pfizer's BD effort - feeding into old criticism around Pfizer's ability to pick winners through BD.\" — Barclays – Sept 25, 2024; \"When you cover biotech and pharma - it's hard to find a headline that's truly jarring, but news that PFE is recalling Oxbryta/discontinuing all active trials after seeing a death/ VOC imbalance in clinical trials & lack of overall risk-benefit fits the bill.\" — Jefferies – Sept 26, 2024", "attrs": null, "subkind": null, "toolName": "Authority citation", "toolSlug": "authority-citation", "confidence": null, "componentId": "019dd953-2b66-7100-896a-a70fa41add7a", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.02, "w": 0.3, "x": 0.01, "y": 0.97 }, "kind": "source-note", "text": "Source: Wall Street research. Quotes are bolded and underlined for emphasis.", "attrs": null, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "4d369e02-b567-4373-89c1-58aba727e86e", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.03, "w": 0.92, "x": 0.04, "y": 0.9 }, "kind": "title", "text": "Wall Street analysts were shocked by Pfizer's recall of OXBRYTA.", "attrs": null, "subkind": "action-title", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "3e5f8307-ad7b-4b65-97a8-ae9e13ac1126", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.11, "w": 0.92, "x": 0.04, "y": 0.03 }, "kind": "title", "text": "Pfizer's Failed GBT Acquisition Shocked the Industry and Raised Serious Questions About Its BD Capabilities", "attrs": null, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "4f171433-fc58-4709-822a-9c0a391fb3b0", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [], "frameworks": [ { "name": "authority-citation", "slug": null, "matchId": "b2563ac8-f5c9-4a2d-b57b-0a41d115fab8", "evidence": "Uses Wall Street analyst quotes to validate a negative thesis about management.", "confidence": 0.9 } ], "arcBeats": [ { "to": 60, "from": 11, "beatId": "06f958bd-fafa-4ea3-a570-c80d16e2354b", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate (Make it worse)", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "The document highlights several issues with Pfizer's strategy, including its poor capital allocation and forecasting and budgeting issues, which have made its performance worse.", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "loops": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "54ce6058-bed8-43c5-8780-84fb43f33c5e", "evidence": "The document highlights the significant losses in value that Pfizer has experienced due to its poor performance, and urges the board to take action to improve this.", "position": 0, "objective": "What are the consequences of not improving Pfizer's performance?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 73, "from": 3, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "f6f940a6-6451-4a43-940f-82e2afbdbeb8", "evidence": "The document presents several potential solutions to improve Pfizer's performance, including improving its return on R&D investments and holding management accountable for improving performance.", "position": 1, "objective": "Can Pfizer achieve higher returns on capital?", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }